Answers are grounded in this paper and cite their sources.
Background Intrahepatic cholestasis of pregnancy (ICP) is associated with increased risk of adverse perinatal outcomes, yet current monitoring lacks predictive accuracy. This study aimed to explore alterations in serum bile acid profiles and their relationship with adverse perinatal outcomes in ICP.Methods This study enrolled 149 pregnant women, including 77 normal pregnant women and 72 cases with ICP, subdivided into ICP with adverse perinatal outcomes and those without according to the perinatal outcomes. Serum concentrations of 15 bile acids were quantified using ultra-performance liquid chromatography-tandem mass spectrometry and compared among the three groups.Results ICP patients exhibited significantly lower gestational age at delivery, Apgar scores, and birth weight, alongside higher rates of cesarean delivery, low birth weight, neonatal intensive care unit admission, meconium-stained amniotic fluid, and preterm birth (all p < 0.05). Twelve bile acids were significantly elevated in ICP (all p < 0.01); notably, taurolithocholic acid elevation was exclusive to the ICP with adverse perinatal outcomes. Glycocholic acid (GCA), glycochenodeoxycholic acid (GCDCA), taurocholic acid (TCA), taurochenodeoxycholic acid (TCDCA), tauroursodeoxycholic acid (TUDCA), and total bile acid levels positively correlated with adverse perinatal outcomes (all p < 0.05). The combined indicator of these six indicators demonstrated superior predictive efficacy for adverse perinatal outcomes with an area under the curve of 0.836, sensitivity of 73.0%, and specificity of 82.9%.Conclusions Distinct serum bile acid metabolic signatures characterize ICP patients with adverse perinatal outcomes. Elevated levels of total bile acids and conjugated bile acids, including GCA, GCDCA, TCA, TCDCA, and TUDCA, were associated with adverse perinatal outcomes and might serve as candidate biomarkers for risk prediction. The multi-bile acid combined indicator demonstrated superior exploratory predictive performance over individual markers, offering a potential tool for identifying high-risk ICP patients, which requires prospective external validation before clinical application.
No takes yet. Share an insight, caveat, or question.
Gou et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: